Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

37.81USD
1:30am IST
Change (% chg)

$0.60 (+1.61%)
Prev Close
$37.21
Open
$37.19
Day's High
$38.06
Day's Low
$37.10
Volume
1,269,783
Avg. Vol
1,356,165
52-wk High
$47.81
52-wk Low
$30.69

Select another date:

Wed, Aug 22 2018

Photo

FDA extends EpiPen expiry date to combat shortage

The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.

Continue Reading

U.S. FDA extends EpiPen expiry date to combat shortage

Aug 21 The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.

FDA approves Teva's generic of Mylan's EpiPen

The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs. | Video

U.S. FDA approves first generic of Mylan's EpiPen

U.S. health regulators on Thursday approved Teva Pharmaceutical Industries Ltd's generic of Mylan NV's EpiPen, making it the first copycat version of the life-saving allergy treatment.

UPDATE 1-U.S. FDA approves first generic of Mylan's EpiPen

Aug 16 U.S. health regulators on Thursday approved Teva Pharmaceutical Industries Ltd's generic of Mylan NV's EpiPen, making it the first copycat version of the life-saving allergy treatment.

U.S. FDA approves first generic version of Mylan's EpiPen

Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's EpiPen for the emergency treatment of allergic reactions.

Mylan eyes 'all alternatives' as quarterly profit falls short

Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers.

Drugmaker Mylan considering strategic alternatives

Aug 8 Drugmaker Mylan NV said on Wednesday it was evaluating a wide range of alternatives, sending its shares down nearly 5 percent before the bell.

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

Mylan signs U.S. license deal on Humira with AbbVie

July 17 AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

Select another date:

Market Views

» More MYL.OQ Market Views